Description
Sarmsamerica manufactures Hexarelin, also known as Examorelin, with the highest quality and potency available. Research on Hexarelin, often referred to as Examorelin, shows that it works by inducing growth hormone secretion from the pituitary gland. Additionally, studies have revealed that Hexarelin can strengthen neural function.
Description of Hexarelin
Hexarelin is a synthetically produced Peptide developed in the early 1990s by the Italian pharmaceutical company Mediolanum Farmaceutici as part of research aimed at finding compounds capable of stimulating the release of growth hormone (GH) from the pituitary gland. Since its development, Hexarelin has been the focus of numerous studies, particularly for its cardio-stimulating and cardioprotective effects. For instance, a specific rat study demonstrated hexarelin’s anti-atherosclerotic activity, where it suppressed the formation of atherosclerotic plaques and neointima.
Additionally, Hexarelin reduced calcium deposition in the aortic wall and lowered cholesterol levels in obese rats. Below, we provide further information on Hexarelin research topics.
Research Confirmed Effects
Hexarelin in Heart Protection
Hexarelin has demonstrated cardioprotective effects in rat models of myocardial ischemia/reperfusion (I/R) injury by binding to the growth hormone secretagogue receptor (GHSR) and receptor CD36. Treatment with Hexarelin resulted in improved cardiac systolic function, decreased levels of malondialdehyde (a marker for oxidative stress), and a higher number of surviving cardiomyocytes compared to those treated with saline. Additionally, the beneficial effects of Hexarelin treatment were found to be slightly superior to those of equimolar ghrelin treatment.
Another study investigated the impact of Hexarelin on male ghrelin-knockout mice after myocardial infarction, providing further evidence of its cardioprotective properties. Hexarelin significantly reduced the mortality rate within two weeks compared to a control group and improved various cardiac function parameters, such as ejection fraction and peak rates of pressure rise and decline. These improvements in cardiac function, along with reduced heart cell death, were achieved through binding to GHSR and preventing apoptosis. Additionally, Hexarelin treatment was shown to be more effective than ghrelin treatment in terms of enhancing heart function.
In a study investigating its therapeutic role, rats with coronary artery ligation (CAL)-induced heart failure were treated with subcutaneous injections of Hexarelin or saline. The results demonstrated that Hexarelin treatment significantly improved left ventricular (LV) function, reduced oxidative stress, and ameliorated myocardial remodeling.
In both mouse and rat models of heart disease, a study examining the impact of Hexarelin on myocardial infarction (MI) found that Hexarelin treatment improved left ventricular function, reduced cardiac fibrosis, and decreased interstitial collagen deposition. This cardioprotective effect was also observed in spontaneously hypertensive rats (SHRs), where Hexarelin treatment reduced left ventricular hypertrophy, improved cardiac function, and lowered blood pressure. The mechanism behind these benefits appears to be related to hexarelin’s ability to modulate the expression of growth hormone secretagogue receptor (GHSR) and its effect on collagen synthesis and degradation.
Hexarelin’s effects on cardiac function and fibrosis are accompanied by a shift from sympathetic to parasympathetic nervous system activity, resulting in lower heart rates and reduced blood pressure. This shift helps reduce myocardial remodeling and supports overall cardiac health.
Hexarelin and Its Cardioprotective Effects in Diabetic Rats
Hexarelin has demonstrated significant cardioprotective effects in various models of heart disease. In one study, it was shown to improve cardiomyocyte function in streptozotocin-induced diabetic rats. This improvement was achieved by reversing changes in cardiomyocyte contraction and intracellular calcium ([Ca2+]i) transients, which are commonly disrupted in diabetic conditions. Additionally, Hexarelin treatment corrected the abnormal action potential duration and transient outward potassium current (Ito) density observed in diabetic cardiomyocytes. The treatment was also associated with anti-apoptotic effects, including upregulated GHSR expression and altered expression of apoptosis-related proteins such as Bax, Bcl-2, caspase-3, and caspase-9. This suggests that Hexarelin may hold therapeutic potential for managing cardiac dysfunction in diabetic patients.
Hexarelin and Improved Fat Measures
Hexarelin also shows potential in improving lipid metabolic aberrations in non-obese insulin-resistant male mice. In a study, mice received twice-daily intraperitoneal injections of Hexarelin for 12 days, resulting in notable improvements in glucose and insulin tolerance, along with decreased plasma and liver triglycerides. These benefits are believed to be connected to hexarelin’s ability to enhance adipocyte differentiation and improve lipid metabolism in white adipose tissue. Although Hexarelin-treated mice exhibited increased food intake, it did not affect their total body weight. In fact, Hexarelin treatment was associated with decreased fat mass and increased lean mass, suggesting it corrected the abnormal body composition often linked to insulin resistance and metabolic syndrome.
Hexarelin and Muscle Protection
Furthermore, the Peptide has been found to protect skeletal muscle from mitochondrial damage in rat models of cisplatin-induced cachexia, a common side effect of cancer chemotherapy. Cachexia is characterized by weight loss and muscle atrophy, and cisplatin treatment can lead to a decrease in mitochondrial biogenesis, mass, and fusion index, along with increased oxidative stress. Studies demonstrated that Hexarelin could reverse these detrimental effects by counteracting chemotherapy-induced mitochondrial dysfunction. This suggests that targeting mitochondrial health could be an effective strategy to mitigate muscle wasting in cachexia.
In addition to its impact on mitochondria, Hexarelin has also shown beneficial effects in preventing the dysregulation of skeletal muscle calcium homeostasis in rat models. This dysregulation contributes to muscle atrophy and is linked to altered calcium signaling pathways. Cisplatin-treated rats exhibited reduced muscle weight, smaller fiber diameter, increased intracellular calcium levels, and decreased calcium transients. Hexarelin treatments helped normalize calcium homeostasis, preserving muscle function and reducing atrophic indicators.
Hexarelin Side Effects
Research shows that Hexarelin Peptide has very mild if any, side effects. Some studies have reported bloating, numbness in the extremities, and fatigue. Hexarelin does not cause estrogenic side effects, liver toxicity, a decrease in testosterone production, or adverse effects on the heart or cholesterol levels.
Hexarelin Structure
| Quantity | 2 mg |
| Unit: | 1 Vial |
| Physical Appearance: | White powder |
| Salt form: | Acetate |
| Peptide Purity: | ≥97% |
| Sequence: | His-2MeDTrp-Ala-Trp-DPhe-Lys-NH2 |
| Molecular Mass: | 887 |
| CAS NO.: | 140703-51-1 |
| Solubility: | NaCl / Sterile / Bacteriostatic water 1ml/vial |
Hexarelin FAQs
What Is the Benefit of Hexarelin Peptides?
The use of Hexarelin increases circulating growth hormone (GH) levels, which in turn causes Insulin-Like Growth Factor (IGF-1) levels to rise in the liver. IGF-1 is the primary driver of muscle growth in response to GH stimulation. Users typically experience increased strength and muscle mass, along with significant fat loss.
Is Hexarelin Better Than Ipamorelin?
Hexarelin has a broader hormone-releasing activity, whereas Ipamorelin is more selective for GH release. Both Peptides offer a wide range of potential therapeutic applications in the field of growth and development.
Does Hexarelin Increase Cortisol?
Hexarelin significantly increased ACTH and cortisol release (area under the curve, 3,444 ± 696 ng/L·125 min and 45,844 ± 2,925 nmol/L·125 min, respectively). This effect was further enhanced by the addition of CRH at a dose that independently produces maximal stimulation (6,580 ± 1,572 ng/mL·125 min and 63,170 ± 2,616 nmol/L·125 min).
What Is the Difference Between MK-677 and Hexarelin?
MK-677, a growth hormone secretagogue that mimics the action of ghrelin, stimulates the pituitary gland to increase growth hormone levels. In contrast, Hexarelin acts as a selective agonist for the ghrelin receptor, directly triggering the release of growth hormone.
Why Buy Hexarelin Peptide at Sarmsamerica
At Sarmsamerica, we provide quality research supplies you can trust, thoroughly testing everything for authenticity and purity. If you’re to buy Hexarelin Peptide in a 2mg vial, we’re here to meet your research requirements. Choose Sarmsamerica for a reliable source and don’t hesitate to contact us If you have any questions.
References:
- E. Agbo et al., “Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats,” Turk. J. Med. Sci., vol. 49, no. 3, May 2019. [PubMed]
- H. McDonald et al., “Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction,” Physiol. Rep., vol. 6, no. 9, p. e13699, 2018. [PubMed]
- X. Xu et al., “Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat,” Am. J. Physiol. Heart Circ. Physiol., vol. 303, no. 6, pp. H703-711, Sep. 2012. [PubMed]
- X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]
- Y. Mao, T. Tokudome, I. Kishimoto, K. Otani, M. Miyazato, and K. Kangawa, “One dose of oral hexarelin protects chronic cardiac function after myocardial infarction,” Peptides, vol. 56, pp. 156–162, Jun. 2014. [PubMed]
- Y. Ma, L. Zhang, J. N. Edwards, B. S. Launikonis, and C. Chen, “Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium,” PloS One, vol. 7, no. 4, p. e35265, 2012. [PloS One]
- R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, 01 2017. [PubMed]
- G. Sirago et al., “Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia,” Sci. Rep., vol. 7, Oct. 2017. [nature.com]
- E. Conte et al., “Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia,” J. Cachexia Sarcopenia Muscle, vol. 8, no. 3, pp. 386–404, Jun. 2017. [PubMed]
- Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]
- Yuanjie Mao, Takeshi Tokudome,1 and Ichiro Kishimoto, „The cardiovascular action of hexarelin,“ [PubMed]
- Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]
- Yuanjie Mao, Takeshi Tokudome, and Ichiro Kishimoto, „The cardiovascular action of hexarelin.“ [PubMed]
- https://pubchem.ncbi.nlm.nih.gov/compound/6918297
- https://academic.oup.com/jcem/article-abstract/78/3/693/2651002?redirectedFrom=fulltext
- https://link.springer.com/article/10.1007%2FBF00191904
- https://academic.oup.com/jcem/article/81/12/4338/2650623
Disclaimer: The Hexarelin currently listed on this site is sold for research use only and is not for human consumption. This product is not a compound, supplement, food, or cosmetic and must not be misused, sold, labeled, or branded as such. These products are not intended to diagnose, treat, or cure any condition or disease. They are strictly for research purposes and not for human use.
